论文部分内容阅读
再生障碍性贫血(AA)是一组表现为骨髓造血功能衰竭和全血细胞减少的疾病。尽管对于重型再生障碍性贫血(SAA)和输血依赖非重型再生障碍性贫血(NSAA)治疗推荐得到公认,但关于NSAA进展的危险因素报道较少,且几乎尚无临床研究正式提出非输血依赖NSAA的治疗方案。对于非输血依赖NSAA,多数血液学专家认为无需治疗仅给予观察即可,但部分研究显示经免疫抑制治疗后出现输血依赖和SAA进展率明显低于其他观察组,因此进行多中心随机研究势在必行。
Aplastic anemia (AA) is a group of diseases characterized by bone marrow hematopoietic failure and pancytopenia. Although recommendations for the treatment of severe aplastic anemia (SAA) and transfusion-dependent non-heavy-form aplastic anemia (NSAA) are well established, there are few reports of risk factors for NSAA progression and few clinical studies have formally proposed non-transfusion dependent NSAA Treatment program. For non-transfusion-dependent NSAA, most hematologists consider it untreated, but some studies have shown that there is a significant reduction in transfusion-dependent and SAA rates following immunosuppressive therapy compared to other groups, and therefore a multicenter randomized study Will do.